Fairbanks Capital Management Inc. raised its position in Allergan PLC. (NYSE:AGN) by 1.3% during the second quarter, Holdings Channel reports. The fund owned 5,480 shares of the company’s stock after buying an additional 70 shares during the period. Allergan PLC. makes up 1.2% of Fairbanks Capital Management Inc.’s investment portfolio, making the stock its 20th largest position. Fairbanks Capital Management Inc.’s holdings in Allergan PLC. were worth $1,332,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Columbus Circle Investors acquired a new position in shares of Allergan PLC. during the first quarter worth approximately $3,937,000. Alta Capital Management LLC boosted its position in shares of Allergan PLC. by 7.2% in the first quarter. Alta Capital Management LLC now owns 161,688 shares of the company’s stock worth $38,630,000 after buying an additional 10,834 shares during the last quarter. Feltz Wealth PLAN Inc. acquired a new position in shares of Allergan PLC. during the first quarter worth approximately $107,000. Nisa Investment Advisors LLC boosted its position in shares of Allergan PLC. by 12.9% in the first quarter. Nisa Investment Advisors LLC now owns 95,746 shares of the company’s stock worth $22,876,000 after buying an additional 10,903 shares during the last quarter. Finally, Bank of The West boosted its position in shares of Allergan PLC. by 11.5% in the first quarter. Bank of The West now owns 19,937 shares of the company’s stock worth $4,763,000 after buying an additional 2,054 shares during the last quarter. Institutional investors own 83.63% of the company’s stock.

Shares of Allergan PLC. (NYSE:AGN) opened at 224.77 on Friday. Allergan PLC. has a 52 week low of $184.50 and a 52 week high of $256.80. The stock’s 50 day moving average is $243.88 and its 200-day moving average is $238.60. The company has a market cap of $75.14 billion, a price-to-earnings ratio of 6.85 and a beta of 1.16.

Allergan PLC. (NYSE:AGN) last posted its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.95 by $0.07. The company had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The firm’s revenue was up 8.8% compared to the same quarter last year. During the same quarter last year, the firm posted $3.35 EPS. On average, equities analysts anticipate that Allergan PLC. will post $16.27 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be paid a $0.70 dividend. This represents a $2.80 annualized dividend and a yield of 1.25%. The ex-dividend date is Wednesday, August 16th. Allergan PLC.’s dividend payout ratio is presently 9.95%.

ILLEGAL ACTIVITY WARNING: “Fairbanks Capital Management Inc. Has $1.33 Million Stake in Allergan PLC. (AGN)” was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/18/fairbanks-capital-management-inc-has-1-33-million-stake-in-allergan-plc-agn.html.

A number of equities analysts recently commented on the stock. Mizuho reiterated a “buy” rating and issued a $267.00 target price on shares of Allergan PLC. in a research report on Wednesday, August 2nd. Royal Bank Of Canada set a $285.00 target price on shares of Allergan PLC. and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Wells Fargo & Company lifted their target price on shares of Allergan PLC. to $278.00 and gave the stock an “outperform” rating in a research report on Thursday, August 3rd. Deutsche Bank AG reiterated a “buy” rating and issued a $273.00 target price (up previously from $265.00) on shares of Allergan PLC. in a research report on Monday, July 17th. Finally, BidaskClub upgraded shares of Allergan PLC. from a “hold” rating to a “buy” rating in a research report on Saturday, June 24th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $275.49.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.